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Objective: To recognize the proﬁle of platelet donors and the proﬁle of the plateletphere-
sis session as well as to investigate the main adverse events of platelet donation using
plateletpheresis and associated risk factors.
Methods: This retrospective, cross-sectional and analytical study was performed with a
quantitative approach by analyzing 316 donation ﬁles from February 2010 to December 2011.
The IBM SPSS Statistics program was used for data processing and analysis. The chi-square
test was used to verify whether there was an association between factors related to the
procedure and the donor, and the adverse events that occurred.
Results: The mean age of platelet donors was 40 years old (standard deviation=8.9), with
the prevalent age group being between 40 and 49 years old; the prevalent blood type was
O positive (53.8%), the mean duration of the procedure was 73min and the mean amount
of anticoagulant used was 360mL. The association between procedure duration and the
volume of anticoagulant was inverse and statistically signiﬁcant; the longer the procedure
and the greater the volume of anticoagulant used, the less adverse reactions occurred.
Conclusion: The low incidence of adverse events indicates that the procedure iswell tolerated
by donors. Obtaining data regarding the incidence of adverse events is a way of promoting
a dynamic review of medical and nursing teams to improve the safety and comfort of the
donor.
© 2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.
transfusion.
The increase in medical and surgical indications for
platelet transfusion, along with the new technologies avail-ntroduction
t is possible to collect the therapeutic unit required for
transfusion in an adult patient from a single donor
sing plateletpheresis. This reduces the risk of immediate
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able, promoted and increased the use of plateletpheresis.2
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and hematocrit before donation were 14.8 g/dL and 44%,
respectively.
Table 1 – Adverse events occurring during
plateletpheresis donation. Uberaba, 2010–2011.
Adverse events n %
Mild reaction 7 2.2
Moderate reaction 1 0.3192 rev bras hematol hem
Plateletpheresis should be performed in a speciﬁc area and
under the guidance and supervision of a physician.3
The plateletpheresis procedure is considered relatively
safe. However, several complications may occur. Anticoagu-
lant (ACD) intoxication, which is due to hypocalcemia, entails
perioral paresthesia of the extremities, tremors, dizziness,
chills, and uncoordinated involuntary movements. Vasova-
gal reaction, which is characterized by pallor, sweating,
nausea, hypotension, fainting and loss of consciousness is
also a possible complication. Hypovolemia and bruising,
which may be related to venipuncture as well as the use
of a tourniquet on the arm for a long time and the con-
tinued movement of the hands, is also another possible
complication.4
This study was proposed due to the lack of national stud-
ies on the issue and the need to understand the risk factors
related to adverse events in platelet donation. This study was
also proposed to provide support for the adoption of measures
to prevent the occurrence of adverse events, minimizing the
impact for the service and for the donor.
The aim of this study was to identify the proﬁle of platelet
donors and the proﬁle of plateletpheresis donations as well
as the major adverse events resulting from plateletpheresis
donation and associated risk factors.
Methods
This is a retrospective, cross-sectional and analytical study
with a quantitative approach. It was developed in the Uber-
aba Regional Blood Center (Minas Gerais), a unit belonging to
Fundac¸ão Hemominas, which collects a total of 14,000 bags of
blood and 180 platelet collections by plateletpheresis annu-
ally. The Blood Center meets the demand of eight cities in the
region through transfusion agencies and ten hospitals located
in the city with blood treatment centers.
Once the research proposal was approved by the Research
Ethics Committee at Fundac¸ão Hemominas (protocol no.
321/2011), an analysis was performed of 316 plateletpheresis
and donation ﬁles, which had been stored in the unit between
February 2010 and December 2011. An instrument, used to
guide data collection, addressed clinical and epidemiologi-
cal aspects, characteristics of plateletpheresis donations and
donors, and the complications that occurred during the proce-
dure, which were reported by the donor and noted by nursing
staff, as per the institutional protocol for recording adverse
events during donation.
The collection of platelets by plateletpheresis in the Blood
Center is performed using a mobile platelet collection system
(Haemonetics MCS®) and meets the following criteria: single
units must contain at least 3.0×1011 platelets in at least 90%
of the units evaluated and double units must contain at least
6.0×1011 platelets; the platelets must be valid for up to ﬁve
days.
Donors are invited by the recruitment department to
donate platelets using the plateletpheresis method. The
donor, in order to donate platelets using this system, must
have a platelet count of 150×109/L for single units and
250×109/L for double units.62014;36(3):191–195
The classiﬁcation of adverse events was based on the clin-
ical manifestations presented by the donor. The following
criteria were used:
(1) Mild clinical complications – syncope, malaise, dizziness,
sweating, paresthesia, headache and paleness;
(2) Moderate medical complications – symptoms with a mild
reaction, nausea, vomiting, hypotension and arrhythmia;
(3) Severe medical complications – the donor has symptoms
of a mild to moderate reaction, hyperventilation, tetany,
apnea, loss of consciousness and convulsive crisis,5 and
hematoma.
The data collected were entered into the Excel® spread-
sheet program (Windows® XP), by double entry for subsequent
validation. The SPSS computer program (version 17.0) was
used for data processing and analysis. Clinical and epidemi-
ological variables were analyzed using descriptive statistics
(absolute, relative and mean frequency).
The chi-square test was used to check whether there was
an association between the independent variables (donor
weight, gender, age, duration of the procedure and volume of
ACD used) and adverse events occurring during the donation
process (dependent variable). The logistic regression test was
used for multivariate analysis. All results with an alpha error
of 5% (p-value<0.05) were considered signiﬁcant.
The analysis of themultiple logistic regression test consists
of a multivariable dependency test, i.e., in order to employ it,
the researcher must deﬁne a qualitative outcome or variable
answer (adverse events) and a set of quantitative explanatory
or categorical variables (risk factors)which relate to those vari-
ables. The result is the Odds Ratio adjusted for the risk factors
considered in the study.7
Results
In terms of donor proﬁle, 310 (98.1%) donors resided in Uber-
aba, 244 (77.2%) were male, and 162 (51.3%) were married. The
mean age was 40 years [standard deviation (SD) = 8.9], with the
most prevalent age group being between 40 and 49 years old
(40.8%).
Themeandonorweightwas 78.7 kg; themeandonor height
was 169 cm; and the mean donor blood volume was 5084mL.
The prevalent blood type was O positive, which accounted
for 53.8% of the donations. The mean values of hemoglobinHematoma 5 1.6
Mild reaction+hematoma 1 0.3
Total 14 4.4
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Table 2 – Association between the adverse events identiﬁed and the variables related to the donor and plateletpheresis procedure. Uberaba, 2010–2011.
Variables Yes No RR (95% CI) OR (95% CI) p-Value AOR (95% CI) p-Valuea Total (n=316)
n % n % n %
Body weight
<80kg 9 4.7 181 95.3 1.194 (0.41–3.48) 1.203 (0.39–3.67) 1 1.862 (0.35–3.77) 0.303 190 60.1
>80kg 5 4 121 96 126 39.9
Gender
Women 5 6.9 67 93.1 1.883 (0.65–5.44) 1.949 (0.63–6.01) 0.324 1.150 (0.57–6.08) 0.817 72 22.8
Men 9 3.7 235 96.3 244 77.2
Age range
≤40 years 9 6.4 132 93.6 2.234 (0.76–6.51) 2.318 (0.76–7.08) 0.17 2.010 (0.63–6.41) 0.238 141 44.6
>40 years 5 2.9 170 97.1 175 55.4
Duration of procedure
<60min 7 12.3 50 87.7 4.544 (1.65–12.44) 5.040 (1.69–15.0) 0.005 3.265 (0.91–11.71) 0.069 57 18
>60min 7 2.7 252 97.3 259 82
ACD volume
<250mL 3 21.4 11 78.6 5.883 (1.84–18.742) 7.215 (1.76–29.6) 0.019 2.790 (0.53–14.59) 0.224 14 4.4
>250mL 11 3.6 291 96.4 302 95.6
ACD: anticoagulant; RR: relative risk; 95% CI: 95% conﬁdence interval; OR: odds ratio; AOR: odds ratio, conﬁdence interval of logistical regression.
a p: signiﬁcance of logistical regression.
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The mean duration of a plateletpheresis session was
73min. The mean amount of platelets estimated for collec-
tion was 3.47×1011, whereas the mean number of platelets
actually collected was 3.6×1011.
The mean volume of blood processed by the equipment
was 2829.8mL, and the mean volume of the product obtained
was 299.55mL. The mean amount of ACD used during the
procedures was 360mL.
As shown in Table 1, a total of 14 (4.4%) donors had
some type of adverse event: seven (2.2%) had mild reac-
tions, one (0.3%) had a moderate reaction, ﬁve (1.6%) had
hematomas, and one (0.3%) had a mild reaction associated
with hematoma.
Among the donorswhopresented complications, themean
number of donations made by these individuals was 8.86
(SD=8.9). Among the donors who suffered adverse events,
two (8.7%) were ﬁrst time platelet donors. Among donors
who had donated up to 10 times, eight (5.8%) had adverse
events, and of the donors who had undergone platelet-
pheresis donation over 11 times, four (2.8%) had adverse
events.
The bivariate and multivariate analyses, presented in
Table 2, show a statistically signiﬁcant association between
the duration of the procedure (less than 60min) and the vol-
ume of ACD infused (less than 250mL) with the occurrence of
adverse events (p<0.05). Nevertheless, adjusting for the other
variables, the volume of ACD was not statistically signiﬁcant,
and the association with the time variable was marginally
signiﬁcant (p=0.069).
Discussion
The potential donor has to meet several requirements to
be accepted as a suitable candidate for blood component
donation.6 Criteria such as hematocrit or hemoglobin levels,
age, weight and minimum platelet count are important for
the safety of the donor.5 Weight or body mass is indicated as
criteria to maximize the donation of plateletpheresis, because
larger donors have higher platelet yields due to the higher
volume of blood.8
Several studies show a common proﬁle for donation, which
is a larger number of male donors.8–12 Some studies also show
that men have lower rates of adverse events compared to
women inplateletpheresis donation. Theﬁndings of this study
are consistent with the literature.
In an investigation that evaluated the performance of
two plateletpheresis devices, the data on the performance
of Haemonetics mobile platelet collection system MCS 3p
were a mean duration of 74.5±3.12min, volume processed
3.2–3.4 L and volume of ACD used 330mL.13 This data cor-
roborates the results of the current study, considering that
similar equipment was used in the donation center. Making
sure that the results of the equipment involved in thedonation
process are similar is essential to provide maximum safety
to the donor and avoid complications due to faulty instru-
ments.
Results showed that 14 donors (4.4%) had some type of
adverse event. This low incidence is consistent with the lit-
erature, which indicates that the plateletpheresis procedure2014;36(3):191–195
is well-tolerated by donors.9 Nevertheless, of apheresis dona-
tions, there are reports that adverse events are more frequent
in plateletpheresis compared to other types such as plasma-
pheresis and leukapheresis.14
One complication, local bruising, was also described in
another study.14 The signiﬁcant presence of bruising as an
adverse event is considered a non-random event15 because
factors such as the experience of the professional perform-
ing the puncture, the number of prior apheresis donations,
the anatomy at the venipuncture, the equipment used and
the diastolic blood pressure are signiﬁcantly correlated to
the development of bruising. Unlike citrate reactions, which
are more likely to occur in individuals who donated many
times, the probability of bruising reduces with the number of
donations.14,16
Other predominant clinical manifestations presented in
the literature are a tingling feeling, numbness,muscle cramps,
tetany or convulsions from reactions to citrate. Vasovagal
reactions, which manifest as paleness, weakness, nausea,
dizziness, vomiting, hypotension, tachycardia, bradycardia,
or fainting, are also possible adverse effects.9 Most of these
symptoms generally occur as moderate to severe adverse
events. Nevertheless, in this study, although some of these
symptoms were observed, mild adverse events were the most
common.
Despite the low incidence of adverse events, studies indi-
cate thatwomen are 2.43–2.8 timesmore affected bymoderate
to severe events than men in apheresis donations,9,10 ﬁgures
that are similar to the results in this study; even though the
difference was not signiﬁcant, 6.9% of the women had adverse
events compared to 3.7% in men.
In contrast, another study found that the female gender
is one of the factors independently associated with the risk
of citrate toxicity and hypotensive events (non-vasovagal) in
apheresis donations. Other factors associated with the risk
of citrate reactions included the height of the donor and the
model of the apheresis machine used. Other factors asso-
ciated with the risk of hypotension included the height of
the donor, plasma collection and the model of the aphere-
sis machine. The results in this study also point out that
onlywomenwere associatedwith complications related to the
venipuncture.17
The present study indicated a marginally signiﬁcant asso-
ciation between the shorter duration of the procedure and
adverse events, with no association related to the volume
of ACD. These ﬁndings differ from a study that shows that
donors who undergo the procedure repeatedly or for pro-
longed periods are susceptible to an accumulation of citrate
as levels exceed the amount that can be metabolized by the
body.16 Another study revealed that adverse events occurred in
apheresis procedures which took more time (mean 77.1min),
and had a lower infusion of ACD (mean 301.5mL) compared to
those without adverse events.10
It was not possible to establish causal relations with the
ﬁndings of this study. Because of the retrospective and cross-
sectional design, as well as the number of adverse events, the
scope of data analysis was limited. The authors suggest that
future studies with a prospective design should be carried out
to allow a better analysis of the associations found in this
study.
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onclusion
ccording to this study, most donors are male, married, with
mean age of 40 years and a mean number of 13.4 donations
y plateletpheresis. This proﬁle indicates loyalty on the part
f donors, who are willing to perform an invasive procedure
s an example of altruism and solidarity with others.
The frequency of adverse events in this type of donation
s low; in this study it was 4.4%. This fact is important for
he recruitment of new donors, as it is essential to guarantee
afety to donors.
Obtaining data on the incidence of adverse events enables
he dynamic review of the medical and nursing teams to
mprove safety and comfort for the donor, to minimize
nderreporting of these events, and to discuss and create a
ational system of hemovigilance for adverse events in dona-
ions.
It is essential that the multidisciplinary teams that directly
ssist donors in blood component donation centers know how
o advise patients during the procedure, and educate them
bout the possibility of adverse events.
Because this is a relatively new procedure, the national lit-
rature doesnot providemuch informationon the subject. The
umber of adverse reactions identiﬁed in this study was low,
nd did not lead to more signiﬁcant and consistent associa-
ions and conclusions. Nevertheless, the authors expect that
his studymay lead to the development andupdate of national
tudies regarding platelet donations by apheresis and the pos-
ible adverse effects.
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